Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

NOVADEL PHARMA INC(OTC BB: NVDL.OB)

9 Posts
| Omlaag ↓
  1. drulletje drie 22 oktober 2010 16:07

    • drulletje drie

      Lid sinds: 04 dec 2003

      Laatste bezoek: 02 mei 2024

    • Aanbevelingen

      Ontvangen: 647

      Gegeven: 186

    •    Aantal posts: 19.204

    Denk dat het oude draadje met het vernieuwen van de site is verdwenen, want ik kan hem niet meer vinden.

    Vorige week onderstaand bericht

    finance.yahoo.com/news/NovaDel-Pharma...

    Sindsdien is de koers geleidelijk aan het stijgen !
    Denk / hoop dat dit het begin is van mooie tijden voor dit aandeel, want er zit nog een hoop in het vat !!

    0,2200 0,0000 (0,00%) 15:59
    Volume laatste transactie 5.000
    Cumulatief volume 283.700
  3. drulletje drie 4 november 2010 15:37

    • drulletje drie

      Lid sinds: 04 dec 2003

      Laatste bezoek: 02 mei 2024

    • Aanbevelingen

      Ontvangen: 647

      Gegeven: 186

    •    Aantal posts: 19.204

    We lopen aardig binnen hier de laatste 2 dagen !

    NovaDel Pharma Inc. Awarded $244,479 Grant from Qualifying Therapeutic Discovery Project Program

    Press Release Source: NovaDel Pharma Inc. On Wednesday November 3, 2010, 2:58 pm EDT

    BRIDGEWATER, N.J.--(BUSINESS WIRE)-- NovaDel Pharma Inc. (OTCBB:NVDL.ob - News), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed pharmaceutical products, today announced that it has been awarded a $244,479 grant under the IRS’ Qualifying Therapeutic Discovery Project, which it expects to receive in January 2011. The grant, which targets therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or to treat chronic or acute diseases and conditions or to result in reduced health care costs, was awarded to NovaDel to help fund the further clinical development of Duromist™. Duromist is NovaDel’s oral spray formulation of sildenafil, and is being developed for the treatment of erectile dysfunction.

    ”We are delighted that the potential advantages of Duromist have been recognized through the award of this grant,” commented Craig Johnson, Senior Vice President and CFO of NovaDel Pharma Inc.

    ABOUT NOVADEL PHARMA

    NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed pharmaceutical products. The Company’s patented oral spray drug delivery technology seeks to improve the efficacy and safety of existing prescription pharmaceuticals, as well as patient compliance and patient convenience. NovaDel has two products that have been approved by the FDA: NitroMist® for the treatment of angina, and Zolpimist™ for the treatment of insomnia. NovaDel’s current product candidates target erectile dysfunction, nausea, migraine headache and disorders of the central nervous system. NovaDel plans to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. To find out more about NovaDel Pharma Inc. (OTCBB:NVDL.ob - News), visit our website at www.novadel.com.

    FORWARD-LOOKING STATEMENTS

    Except for historical information contained herein, this document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability of third parties to commercialize the Company’s products, the successful completion of its clinical trials, including pilot pharmacokinetic feasibility studies, the successful completion of its preclinical studies, the ability to develop products (independently and through collaborative arrangements), the Company’s ability to obtain additional required financing to fund its research programs, the ability to commercialize and obtain FDA and other regulatory approvals for products under development, and the acceptance in the marketplace for oral spray products. The filing of an NDA with the FDA is an important step in the approval process in the United States. Acceptance for filing by the FDA does not mean that the NDA has been or will be approved, nor does it represent an evaluation of the adequacy of the data submitted. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company’s control.

    In addition, our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any of our products could materially impact the Company's actual results. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company’s most recent Quarterly Report on Form 10-Q for the period ended June 30, 2010 filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings
  4. drulletje drie 4 november 2010 15:38

    • drulletje drie

      Lid sinds: 04 dec 2003

      Laatste bezoek: 02 mei 2024

    • Aanbevelingen

      Ontvangen: 647

      Gegeven: 186

    •    Aantal posts: 19.204

    NovaDel Pharma Inc. Receives $500,000 Milestone Payment

    Press Release Source: NovaDel Pharma Inc. On Thursday November 4, 2010, 9:00 am EDT

    BRIDGEWATER, N.J.--(BUSINESS WIRE)-- NovaDel Pharma Inc. (OTCBB:NVDL.ob - News) today announced that it has received a $500,000 milestone payment in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC. The agreement provides Mist Acquisition, LLC with a license to manufacture and commercialize NitroMist® in North America. NitroMist is NovaDel’s oral spray formulation of nitroglycerin, which has been approved by the FDA for acute relief of an attack of angina pectoris, or acute prophylaxis of angina pectoris, due to coronary artery disease.

    ABOUT NOVADEL PHARMA

    NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed pharmaceutical products. The Company’s patented oral spray drug delivery technology seeks to improve the efficacy and safety of existing prescription pharmaceuticals, as well as patient compliance and patient convenience. NovaDel has two products that have been approved by the FDA: NitroMist® for the treatment of angina, and Zolpimist™ for the treatment of insomnia.

    NovaDel’s current product candidates target erectile dysfunction, nausea, migraine headache and disorders of the central nervous system. NovaDel plans to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. To find out more about NovaDel Pharma Inc. (OTCBB:NVDL.ob - News), visit our website at www.novadel.com.

    FORWARD-LOOKING STATEMENTS

    Except for historical information contained herein, this document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability of third parties to commercialize the Company’s products, the successful completion of its clinical trials, including pilot pharmacokinetic feasibility studies, the successful completion of its preclinical studies, the ability to develop products (independently and through collaborative arrangements), the Company’s ability to obtain additional required financing to fund its research programs, the ability to commercialize and obtain FDA and other regulatory approvals for products under development, and the acceptance in the marketplace for oral spray products. The filing of an NDA with the FDA is an important step in the approval process in the United States. Acceptance for filing by the FDA does not mean that the NDA has been or will be approved, nor does it represent an evaluation of the adequacy of the data submitted. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company’s control.

    In addition, our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any of our products could materially impact the Company's actual results. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company’s most recent Quarterly Report on Form 10-Q for the period ended June 30, 2010 filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings.

  7. drulletje drie 8 november 2010 15:49

    • drulletje drie

      Lid sinds: 04 dec 2003

      Laatste bezoek: 02 mei 2024

    • Aanbevelingen

      Ontvangen: 647

      Gegeven: 186

    •    Aantal posts: 19.204

    inderdaad maar het kan snel gaan natuurlijk!

    een goedkeuring en we stijgen nog een stuk harder....
    lekker laten liggen en eventueel bijkopen...
9 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.286
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.434
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.928
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.441
Aedifica 2 832
Aegon 3.257 320.084
AFC Ajax 537 7.018
Affimed NV 2 5.761
ageas 5.843 109.778
Agfa-Gevaert 13 1.862
Ahold 3.536 73.983
Air France - KLM 1.024 34.344
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.773
Alfen 12 16.461
Allfunds Group 3 1.210
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 336
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.765
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.337
AMG 965 125.811
AMS 3 73
Amsterdam Commodities 303 6.522
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.137
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.622
Arcelor Mittal 2.024 318.639
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.107
Aroundtown SA 1 176
Arrowhead Research 5 9.280
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.695
ASML 1.762 77.013
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.654
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Macro & Bedrijfsagenda

  1. 02 mei

    1. Chinese beurzen gesloten ivm Labor Day
    2. ArcelorMittal Q1-cijfers
    3. DSM Firmenich Q1-cijfers
    4. ING Q1-cijfers
    5. BAM Q1-cijfers
    6. ForFarmers Q1-cijfers
    7. Aedifica Q1-cijfers
    8. HelloFresh Q1-cijfers
    9. Shell Q1-cijfers
    10. RELX 41,8 pence ex-dividend
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda